IP Library Granted Patent US 9,981,986
Granted Patent B2
US 9,981,986 · App. 15/354,453 · Granted May 29, 2018

Antimicrobial compounds

Inventors: Mark Moloney (Oxford, GB); Yong-chu Jeong (Oxford, GB)
Assignee: Oxford University Innovation Limited
C07D513/04A01N43/78A01N43/90A01N45/00A01N55/02C07D277/06C07D498/04C07F7/1804
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,981,986
App. No.
15/354,453
Granted
May 29, 2018
Kind
B2
Abstract

The present invention relates to certain tetramic acid derivatives and, in particular, bicyclic tetramic acid derivatives that are suitable for use in the preparation and development of antimicrobial (e.g. antibacterial or antifungal) compositions. The present invention also relates to the use of such compounds as antimicrobial (e.g. antibacterial or antifungal agents) and, in particular, as topical antibacterial or antifungal agents.

Claims (39)

1. A method of treating a microbial infection in a subject in need thereof, the method comprises administering an antimicrobial composition to the subject, wherein the antimicrobial composition comprises a compound of the formula II below:

wherein:

X is O, S or SO 2 ,

R 1 and R 2 are each independently selected from H and C 1 to C 6 alkyl,

R 3 is selected from a functional group selected from H, C 1 to C 6 alkyl, and a carbonyl-containing group,

R 12 is H, alkenyl, aryl, trihaloalkyl and C 1 to C 6 alkyl,

R 7 is a group of the formula L 1 -L 2 -R 6 or L 2 -L 1 -R 6 ,

where L 1 is a linker of the formula —[CR 8 R 9 ] n —, where n is an integer of from 0 to 12, and R 8 and R 9 are each independently selected from H or C 1 to C 2 alkyl, and

where L 2 is absent or a linker that is selected from O, S, SO, SO 2 , N(R′), C(O), C(O)O, OC(O), [O(CR′ 2 ) r ] s , [(CR′ 2 ) r O] s CH(OR′), C(O)N(R′), N(R′)C(O), N(R)C(O)N(R′), SO 2 N(R′) or N(R′)SO 2 where R′ and R″ are each independently selected from hydrogen and a C 1 to C 2 alkyl, and where r is 1 or 2 and s is 1 to 4, and

where R 6 is selected from OR 13 , heterocyclic and C 1 to C 25 hydrocarbyl group, wherein R 13 is a C 1 to C 6 alkyl, and said heterocyclic and hydrocarbyl group is optionally substituted with at least one functional group selected from alkenyl, alkyl, aryl, halo, trihaloalkyl, alcohol, keto, S(O)R 13 , sulfonyl, thio-alcohol, ester, thioester, ether, thioether, amide, thioamide, urea, thiourea, ═O, ═S, amine and heterocyclic group;

or tautomer, salt, or solvate thereof.

2. The method as claimed in claim 1 , wherein n is 0 or 1 and L 2 is absent.

3. The method as claimed in claim 1 , wherein R 6 is a straight chain, branched or cyclic C 6 to C 19 alkyl.

4. The method as claimed in claim 1 , where R 6 is an alkyl that is a bridged ring system.

5. The method as claimed in claim 1 , wherein R 6 is an alkyl group selected from adamantyl, myrtanyl, cyclohexyl and a C 6 to C 19 non-cyclic aliphatic alkyl group.

6. The method as claimed in claim 1 , wherein R 6 is a phenyl group that is optionally substituted with at least one functional group selected from alkyl, aryl, halo, trihaloalkyl, alcohol, thio-alcohol, ester, thioester, ether, thioether, amide, thioamide, urea, thiourea and heterocyclic group.

7. The method as claimed in claim 6 , wherein the phenyl group is substituted with a group selected from cyclohexyl, C 1 to C 3 alkyl, halo, trihalo(C 1 to C 3 ) alkyl, OH, SH, heterocyclic and OR 10 or SR 10 , where R 10 is a C 1 to C 4 alkyl or phenyl group.

8. The method as claimed in claim 6 , wherein the phenyl group is substituted with a heterocyclic group selected from a piperidine and morpholine group, or where the phenyl group is fused to an aromatic heterocyclic ring.

9. The method as claimed in claim 8 , wherein said aromatic heterocyclic ring is a pyrrole ring.

10. The method as claimed in claim 1 , wherein R 3 is selected from H, methyl, C(O)R 11 , and C(O)O[CR 8 R 9 ] n OR 11 , where R 11 is a C 1 to C 4 alkyl group.

11. The method as claimed in claim 1 , wherein R 2 is H.

12. The method as claimed in claim 1 , wherein R 1 is selected from H, methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl, i-butyl and t-butyl.

13. The method as claimed in claim 12 , wherein R 1 is t-butyl.

14. The method as claimed in claim 1 , wherein the compound has the formula:

15. The method as claimed in claim 1 , wherein the composition is a medicament, cosmetic, or suncream.

16. The method as claimed in claim 1 , wherein the microbial infection is a topical microbial infection.

17. The method as claimed in claim 1 , wherein the composition is a topical composition.

18. The method as claimed in claim 1 , wherein the subject is a human or animal.

19. A method of inhibiting bacterial RNA polymerase and/or undecaprenyl pyrophosphate synthase, said method comprises contacting a cell with an effective amount of a compound of the formula II below:

wherein:

X is O, S or SO 2 ,

R 1 and R 2 are each independently selected from H and C 1 to C 6 alkyl,

R 3 is selected from a functional group selected from H, C 1 to C 6 alkyl, and a carbonyl-containing group,

R 12 is H, alkenyl, aryl, trihaloalkyl and C 1 to C 6 alkyl,

R 7 is a group of the formula L 1 -L 2 -R 6 or L 2 -L 1 -R 6 ,

where L 1 is a linker of the formula —[CR 8 R 9 ] n —, where n is an integer of from 0 to 12, and R 8 and R 9 are each independently selected from H or C 1 to C 2 alkyl, and

where L 2 is absent or a linker that is selected from O, S, SO, SO 2 , N(R′), C(O), C(O)O, OC(O), [O(CR′ 2 ) r ] s , [(CR′ 2 ) r O] s CH(OR′), C(O)N(R′), N(R′)C(O), N(R′)C(O)N(R′), SO 2 N(R′) or N(R′)SO 2 where R′ and R″ are each independently selected from hydrogen and a C 1 to C 2 alkyl, and where r is 1 or 2 and s is 1 to 4, and

where R 6 is selected from OR 13 , heterocyclic and C 1 to C 25 hydrocarbyl group, wherein R 13 is a C 1 to C 6 alkyl, and said heterocyclic and hydrocarbyl group is optionally substituted with at least one functional group selected from alkenyl, alkyl, aryl, halo, trihaloalkyl, alcohol, keto, S(O)R 13 , sulfonyl, thio-alcohol, ester, thioester, ether, thioether, amide, thioamide, urea, thiourea, ═O, ═S, amine and heterocyclic group;

or tautomer, salt, or solvate thereof.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 10, 2021
From: OXFORD UNIVERSITY INNOVATION LIMITED
To: OXFORD ANTIBIOTIC GROUP GMBH
Reel/Frame 055211/0890 →
Priority Claims (1)
GB 1211202.5 · Jun 25, 2012 · national
Continuity (2)
Division 14410559
Related Publication 20170066784A1 · Mar 9, 2017